Lindsay Fourman, MD, is an endocrinologist at Massachusetts General Hospital and assistant professor of medicine at Harvard Medical School

When to Add GLP-1 Receptor Agonists to Metreleptin in Lipodystrophy, With Lindsay Fourman, MD

"If a patient is on metreleptin and you're looking to add another agent, a GLP-1 receptor agonist might be a good option,” Lindsay Fourman, MD, endocrinologist at Massachusetts General Hospital and assistant professor of medicine at Harvard Medical School, told 

The comments come alongside new real-world data presented at 

Endocrine Society (ENDO) Annual Meeting 2026

, showing that nearly 1 in 5 adults receiving sustained metreleptin therapy for lipodystrophy subsequently initiated sustained GLP-1 receptor agonist therapy. While the descriptive analysis did not assess efficacy, it highlights growing clinical adoption of the combination and the need for prospective studies.

Metreleptin is approved by the US Food and Drug Administration (FDA) as leptin replacement therapy for complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy.

Since lipodystrophy is associated with severe insulin resistance, diabetes, hypertriglyceridemia, and ectopic fat accumulation, investigators have begun exploring GLP-1 receptor agonists as adjunctive therapy. Early retrospective and preclinical data suggest these agents may improve metabolic outcomes, supporting interest in combination treatment with metreleptin, although the available evidence remains limited and largely observational.

While the rationale for combination therapy includes potential metabolic benefits, clinicians should consider patients’ baseline health status, including pancreatitis risk and elevated triglyceride levels.

“In terms of who you'd hesitate with, there is this kind of cloud around the question of pancreatitis. A lot of data speaks against it now, so we're not so worried about pancreatitis with GLP-1s, but it is a little bit of a hesitation. If a patient just had pancreatitis, I would give it some time for resolution of that episode before starting. I might wait 6 months or something. I also try to get triglycerides down because that can be the trigger for pancreatitis.”

Once a GLP-1 receptor agonist has been initiated in a patient receiving metreleptin therapy, Fourman emphasized the importance of ongoing monitoring. Since metreleptin has been associated with hypoglycemia, blood glucose should be closely tracked, and she recommended the use of a continuous glucose monitor during titration for safety.

Ultimately, Fourman noted that case series suggest GLP-1 receptor agonist monotherapy in lipodystrophy may reduce HbA1c by about 1 to 2%, while combination therapy with metreleptin has been associated with reductions of 2 to 3% or greater in some cases, suggesting a response that may be more synergistic than simply additive. However, she emphasized that additional data are needed before the combination can be incorporated into routine clinical practice.

Editor’s Note: Fourman reports relevant disclosures with Theratechnologies, Chiesi Farmaceutici, and Rhythm Pharmaceuticals.

Fourman T, Berria R, Zadeh E, et al. Real-World Prescribing Patterns of Combined Metreleptin and GLP-1 Receptor Agonist Therapy in Adults with Lipodystrophy. Poster presented at: Endocrine Society; June 13-17, 2026; Chicago, Ill.

Lebenthal Y, Halperin S, Interator H, Brener A, Brown R. American Diabetes Association. Published March 19, 2025. Accessed June 26, 2026. 

https://diabetesjournals.org/care/article/48/5/e71/158022/Oral-Glucagon-Like-Peptide-1-Analog-as-an-Adjuvant

Videos

Real-world data highlight GLP-1 receptor agonist use with metreleptin in lipodystrophy and clinician guidance on timing and safety monitoring.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

This page also hosts content previously published by EndocrinologyNetwork. 


Diana Isaacs, PharmD, is an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic.

Diabetes Dialogue: Tegoprubart and Freedom from Insulin in Type 1 Diabetes

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!

To begin the episode, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss recent advances in type 1 diabetes (T1D) research following presentations at the American Diabetes Association (ADA) Scientific Sessions and the American Association of Clinical Endocrinology (AACE) Annual Meeting. They focus on promising data from an islet cell transplantation study in which all 12 participants achieved insulin independence, with some maintaining normal glycemia for up to 2 years after transplantation.

Isaacs explains that the transplanted islet cells restore endogenous insulin production and emphasizes that the study’s most notable innovation is its immunosuppression strategy. Rather than relying on calcineurin inhibitors such as tacrolimus, which are associated with significant toxicities, particularly nephrotoxicity, the investigators used the investigational anti-CD40 ligand therapy tegoprubart. The hosts discuss how this approach may improve the long-term safety and feasibility of islet transplantation and note ongoing efforts to develop more convenient formulations beyond the current intravenous infusion administered every 3 weeks.

The conversation then turns to the clinical significance of the findings. Bellini highlights that all 12 enrolled participants achieved insulin independence, distinguishing these results from earlier transplantation efforts such as the Edmonton protocol. The hosts also describe the substantial improvements in quality of life reported by participants, including sustained HbA1c values in the normal range without restrictive dietary practices and complete resolution of severe hypoglycemia. Because the trial enrolled individuals with recurrent, life-threatening hypoglycemia, they emphasize that the observed benefits are particularly meaningful for this high-risk population.

The hosts also examine several unanswered questions that remain before this approach can become widely available. They discuss the durability of insulin independence, the long-term need for immunosuppressive therapy, treatment costs, and the challenges associated with scaling islet transplantation beyond specialized research centers. Additional findings are reviewed, including the need for repeat transplantation in 2 participants and observations suggesting that individuals with higher body mass index may require greater islet mass to achieve insulin independence. They also discuss the use of tirzepatide in 2 participants, raising questions about the role of insulin resistance and adjunctive therapies following transplantation.

Broadening the discussion, Isaacs and Bellini review several emerging strategies aimed at expanding access to curative therapies. These include stem cell-derived islets, large-scale beta cell manufacturing, gene-editing approaches, and encapsulation technologies intended to protect transplanted cells while reducing or eliminating the need for chronic immunosuppression. Drawing on presentations from Aaron Kowalski, PhD, and Laura Jacobsen, MD, they emphasize that despite major advances in continuous glucose monitoring, automated insulin delivery systems, and adjunctive pharmacotherapy, subcutaneous insulin administration remains fundamentally nonphysiologic and cannot fully eliminate long-term complications or disease burden.

The episode concludes with a broader discussion of the future of type 1 diabetes research. The hosts highlight efforts to expand eligibility for islet transplantation trials, including studies involving individuals with chronic kidney disease who were previously excluded because of concerns surrounding traditional immunosuppressive therapies. They also underscore the importance of continuing to pursue disease-modifying therapies despite improvements in diabetes technology, emphasizing that glycemic targets alone do not eliminate complications or address disparities in access to care. While acknowledging that a universally applicable cure remains years away, Isaacs and Bellini conclude that the field is making meaningful progress toward safe, durable, and scalable therapies capable of fundamentally changing the treatment of type 1 diabetes.

Editors’ Note: Isaacs reports disclosures with Dexcom, Abbott, Lilly, Novo Nordisk, Medtronic, Insulet, and others. Bellini reports disclosures with Abbott Diabetes Care, MannKind, Povention Bio, and others.

Breakthrough T1D. All 12 Clinical Trial Participants Off External Insulin: New Data on Tegoprubart Continues to Impress. June 7, 2026. Accessed June 29, 2026. 

https://www.breakthrought1d.org/news-and-updates/tegoprubart-islet-transplant-all-participants-off-external-insulin/

Podcasts

This episode covers the recent release of new data on Eledon’s tegoprubart for islet cell transplantation in patients with T1D.

Type 1 Diabetes

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Diabetes Dialogue

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives is a monthly podcast hosted by Diana Isaacs, PharmD, and Natalie Bellini, DNP, aimed at providing a regular roundup of the latest clinically applicable insights across diabetes and metabolic diseases, with a focus on leveraging technology to improve care.

Strategic Alliance Partnership

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

Ziad Obermeyer, MD | Image Credit: UC Berkeley

A new artificial intelligence (AI) tool developed by UC Berkeley routinely outperformed standard clinical tests in identifying patients at risk of 

Clinicians have long understood that sudden cardiac arrest is theoretically preventable with defibrillators. However, without an efficient way of identifying which patients may be at risk, this strategy is extremely difficult to implement reliably. The only predictive biomarker for this condition, cardiac left ventricular ejection fraction (LVEF), notoriously misses most sudden cardiac deaths. Currently, cardiac arrhythmias cause >100,000 sudden deaths in the US every year, despite the availability of these implanted defibrillators, which can find and terminate these arrhythmias before they can result in mortality.

“One thing that makes the problem very tragic, but also very well suited for AI, is that we have the cure for this problem,” Ziad Obermeyer, MD, an associate professor at the School of Public Health at UC Berkeley and the lead author of the study, said in a statement. “If you knew you were one of the people who was going to drop dead, you would go to a cardiologist, and you’d get a defibrillator implanted. The problem is that doctors can’t figure out who needs one before it’s too late.”

Obermeyer and colleagues collected >440,000 electrocardiogram (ECG) records from patients in Sweden, linking them to data from death certificates, and fed these data into a deep learning program. They also included scans from healthy patients, aiming to train the model to recognize cardiac waveform patterns for those who later suffered sudden cardiac arrest.

The program isolated the highest-risk group from the records provided, accounting for roughly 2.2% of the sample. These patients exhibited a 7% annual rate of sudden cardiac arrest, which was higher than patients with reduced LVEF, which made up 1.9% of the sample with a 4.6% annual rate. Roughly 86.1% of the high-risk patients were not flagged by LVEF, indicating the insufficiency of this biomarker. Additionally, patients who had high-risk ECG records who had been implanted with defibrillators were 54.4% less likely to die than expected, according to the model.

A second phase of the study is currently ongoing, in which Obermeyer and colleagues will validate the model externally, working with a US health system and a Taiwanese hospital registry. The former will focus on predicting ventricular arrhythmias that may cause sudden cardiac arrest, while the latter will predict future arrhythmic cardiac arrests. For those scans flagged as high-risk, clinicians will then notify patients, offering them a patch to continually monitor their heart. This data could, according to the press release, allow clinicians to better understand the physiological mechanism within the heart.

The team has assembled a website where individuals who want to assess their own risk can submit basic information and their email address, which will allow the team to contact them for analysis when the AI becomes more widely available. The site can be reached 

. The information from this site, along with the ongoing second phase of the study, will afford Obermeyer and colleagues additional testing data in a specialty with a lack of accessible patient records.

“Good AI starts with good data,” Obermeyer said in a statement. “Unfortunately, data like the ones we used for this study are incredibly hard to access. It’s a big part of why there’s so little clinical AI in use today.”

Pohl J. With AI, researchers discover new way to detect sudden cardiac death risk. 

. June 24, 2026. Accessed June 29, 2026. 

https://news.berkeley.edu/2026/06/24/with-ai-researchers-discover-new-way-to-detect-sudden-cardiac-death-risk/

Obermeyer Z, Schubert A, Ross J, Mullainathan S, Lingman M. An ECG biomarker for sudden cardiac death discovered with Deep Learning. Nature. Published online June 24, 2026. 

Articles

A UC Berkeley deep-learning model trained on >440,000 Swedish ECGs linked to death certificates identified a small subgroup with markedly elevated sudden cardiac arrest risk, outperforming left ventricular ejection fraction (LVEF). The top 2.2% risk stratum showed a 7% annual arrest rate versus 4.6% among reduced-LVEF patients, and most high-risk patients were not captured by LVEF. Ongoing validation across US and Taiwanese datasets will pair high-risk flags with longitudinal patch monitoring to refine mechanisms and prospective detection.

A study from UC Berkeley has unveiled an AI model that outperforms standard clinical tests in identifying patients at risk of sudden cardiac death.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Arrhythmia

New AI Tool May Effectively Predict Sudden Cardiac Arrest Risk in Otherwise Healthy Patients

Victoria Johnson joined MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and is now an assistant managing editor for HCPLive and RheumatologyLive. She doesn’t have enough time for her numerous hobbies. You can reach her at vjohnson@mjhlifesciences.com.

The US Food and Drug Administration (FDA) has approved risankizumab-rzaa (SKYRIZI) for children aged 6 years or older with moderate to severe

who are candidates for systemic therapy or phototherapy, as well as for pediatric patients aged 6 years or older with active psoriatic arthritis (PsA), according to a June 26, 2026, announcement from AbbVie.

The approval also adds a 55-mg prefilled syringe intended to support weight-based dosing for children weighing less than 40 kg; the 150-mg prefilled syringe and pen remain approved for patients weighing 40 kg or more. 

“At Week 16 in part 2 of the OptIMMize psoriasis clinical trial program, risankizumab demonstrated clinically meaningful improvements in sPGA and PASI responses, with responses maintained long-term with continued treatment,” said Amy S. Paller, MD.

Expanding Pediatric Use of Risankizumab in Psoriatic Disease

Risankizumab is now the first IL-23 inhibitor approved in the United States for pediatric patients aged 6 years or older weighing less than 40 kg with plaque PsO or PsA. The announcement did not include the FDA approval letter or a revised prescribing information document beyond the safety and use information summarized in the release.

Risankizumab is a humanized immunoglobulin G1 monoclonal antibody targeting interleukin-23 through selective binding to the p19 subunit.

 IL-23 is involved in inflammatory pathways relevant to several immune-mediated diseases. The drug is already approved by the FDA and European Medicines Agency for adult plaque PsO, PsA, Crohn disease, and ulcerative colitis, according to the company announcement.

Pediatric PsO is a clinically distinct treatment setting because long-term disease control, growth, administration burden, and caregiver involvement can influence treatment selection. Joint American Academy of Dermatology–National Psoriasis Foundation guidance notes pediatric PsO can require topical therapy, phototherapy, systemic nonbiologic therapy, or biologic therapy depending on severity and treatment response.

 Juvenile PsA remains less common than adult PsA, with heterogeneity in presentation and overlap with juvenile idiopathic arthritis categories.

What the OptIMMize Pediatric Psoriasis Program Reported

The pediatric plaque PsO approval was supported by the phase 3 OptIMMize PsO clinical trial program (NCT04435600 and NCT04862286).

 AbbVie described the program as including 2 lead-in pharmacokinetic cohorts, a randomized efficacy assessor-blinded active-controlled cohort enrolling patients aged 12 to younger than 18 years, and a single-arm open-label cohort enrolling patients aged 6 to younger than 12 years.

The company reported risankizumab was associated with improvements in static Physician Global Assessment and Psoriasis Area and Severity Index responses at week 16 in part 2 of OptIMMize, with responses maintained longer term during continued treatment.

 Numeric response rates, confidence intervals, comparator results, and detailed durability data were not included in the June 26 announcement. The absence of those data limits independent assessment of effect size from the press release alone.

For pediatric PsA, the approval was supported by the OptIMMize psoriasis program plus population pharmacokinetic modeling and simulation based on well-controlled adult psoriatic arthritis studies, according to AbbVie.

 This approach indicates the pediatric PsA indication was not described in the announcement as being supported by a dedicated randomized pediatric psoriatic arthritis efficacy trial.

Approximately 30% of individuals who develop PsO have symptoms before age 18 years, according to the pediatric psoriasis guideline cited in the company announcement.

 Pediatric psoriatic disease can affect skin, joints, function, and quality of life, although the magnitude and domains of burden vary by age, disease phenotype, and severity.

Safety Findings and Remaining Data Questions for Pediatric Clinicians

AbbVie reported the safety profile observed among pediatric patients with plaque PsO treated with risankizumab was consistent with the established adult plaque PsO safety profile.

 The announcement did not provide pediatric adverse event rates, serious adverse event rates, discontinuation rates, or laboratory abnormality data from OptIMMize.

The safety information included in the announcement lists serious allergic reactions and infections among important risks.

 The company states clinicians should evaluate patients for infections and tuberculosis before treatment and monitor for tuberculosis during and after therapy. The most common adverse events (AEs) listed for plaque psoriasis and psoriatic arthritis include upper respiratory infections, headache, fatigue, injection-site reactions, and fungal skin infections.

 The announcement also notes liver problems have occurred in treatment for Crohn disease or ulcerative colitis, including a case involving liver test abnormalities with rash requiring hospitalization after intravenous treatment in a person with Crohn disease.

Unanswered questions include the numerical efficacy and safety results from each pediatric cohort, comparative performance against active control, and long-term safety outcomes in younger children receiving weight-based dosing. Peer-reviewed publication of the OptIMMize pediatric data and updated FDA labeling would provide additional detail for assessing the risk-benefit profile in pediatric psoriatic disease.

AbbVie. SKYRIZI® (risankizumab-rzaa) now FDA approved for pediatric use in psoriatic disease. PRNewswire. Published June 26, 2026. 

https://www.prnewswire.com/news-releases/skyrizi-risankizumab-rzaa-now-fda-approved-for-pediatric-use-in-psoriatic-disease-302812335.html

Menter A, Cordoro KM, Davis DMR, et al. Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. 

. 2020;82(1):161-201. doi:10.1016/j.jaad.2019.08.049

Brunello F, Tirelli F, Pegoraro L, et al. New insights on juvenile psoriatic arthritis. 

. 2022;10:884727. doi:10.3389/fped.2022.884727

FDA approval extends risankizumab-rzaa to pediatric patients aged ≥6 years with moderate-to-severe plaque psoriasis eligible for systemic therapy/phototherapy and to active psoriatic arthritis in the same age group. A new 55‑mg prefilled syringe enables weight-based dosing for children <40 kg, while 150‑mg devices remain for ≥40 kg. Supportive evidence includes phase 3 OptIMMize pediatric psoriasis studies showing week-16 sPGA/PASI improvements with durability on continued therapy. Pediatric PsA support relied on psoriasis data plus adult PsA PK modeling, with limited disclosed numerical outcomes.

FDA approved risankizumab for children aged 6 years or older with plaque psoriasis or active psoriatic arthritis.

FDA News

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Rheumatology

Rheumatology condition center page is a comprehensive resource for clinical news and insights on rheumatologic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for arthritis, gout, nr-AxSpA, and more.

FDA Approves Risankizumab for Pediatric Plaque Psoriasis, Psoriatic Arthritis

Larence Leiter, MD, is the director of the Lipid Clinic and associate director of the Clinical Nutrition and Risk Factor Modification centre at St. Michael’s Hospital in Toronto.

Lawrence Leiter, MD | Image Credit: University of Toronto

GLP-1 receptor agonists entered clinical practice as glucose-lowering agents, but the therapeutic rationale for their use has expanded well beyond glycemia. Cardiovascular outcomes trials established mortality and MACE benefits in high-risk patients with type 2 diabetes, and subsequent data have extended the evidence base to include chronic kidney disease, metabolic dysfunction-associated steatohepatitis, obstructive sleep apnea, and osteoarthritis. Most recently, a cluster of real-world analyses presented at the 2026 ASCO Annual Meeting suggested GLP-1 RAs may reduce metastatic progression across 4 obesity-related tumor types — lung, breast, colorectal, and liver — with patients on GLP-1 RAs 38% to 50% less likely to progress to stage IV disease compared with those on DPP-4 inhibitors.

The expanding benefit profile of incretin-class agents coincides with a long-overdue reconceptualization of how comorbidities cluster in clinical practice. In 2023, the AHA issued a presidential advisory formally defining cardiovascular-kidney-metabolic (CKM) syndrome, and in June 2026, the ACC, AHA, ADA, and ASN jointly published the first-ever clinical practice guideline for its prevention and management — with staging recommendations applicable to both adults and youth. The guideline reflects a shift away from siloed organ-specific treatment and toward integrated, multidisciplinary management of interconnected cardiometabolic risk. GLP-1 RAs, with demonstrated benefits across multiple components of CKM syndrome, are well-positioned as a potential foundational therapy within this framework — addressing polypharmacy concerns while targeting several comorbidities simultaneously.

Lawrence A. Leiter, MD, FRCPC, FACP, professor of medicine and nutritional sciences at the University of Toronto and director of the Lipid Clinic at St. Michael's Hospital, spoke with HCPLive at the 

 in Philadelphia to discuss the evolution of incretin-class agents and their role in CKM syndrome management.

Q&A: GLP-1 Receptor Agonists and the Advent of CKM Syndrome, With Lawrence Leiter, MD

HCPLive: Are incretin-based therapies still understood primarily as glucose-lowering agents with pleiotropic effects, or more as systemic metabolic regulators that transcend glycemic control as the primary endpoint?

Our understanding of the GLP-1 RAs and other GLP-1-like drugs has evolved over the years. They were originally developed as glucose lowering agents, and then we recognized that they can be associated with significant weight loss. Now, of course, we have evidence for cardiovascular risk reduction, for improvements in kidney disease, improvements in liver disease, sleep apnea, osteoarthritis, and the list goes on and on. Currently, there's a suggestion that their anti-inflammatory effects may have other beneficial, have other benefits. At the recent cancer meeting, there were 40 different papers talking about the potential benefits of GLP-1 RAs against cancer, so these are remarkable agents, and we're just learning more and more about their potential benefits.

HCPLive: Does the breadth of clinical benefit observed with incretins suggest a shift away from disease-specific treatment paradigms towards more integrated cardiometabolic risk modification?

Recently, there has been a long overdue recognition that we shouldn't be treating individual diseases – they cluster together. Finally, the AHA has now come out with statements on the CKM - cardio kidney metabolic - syndrome, and very recently specific guidelines to treat that. I think one of the potential benefits of the incretin class is that they will treat many disorders within this CKM syndrome. Our patients are pushing back against polypharmacy, and here we have agents that can improve many of the comorbidities associated with the CKM syndrome.

HCPLive: Do you see incretins becoming foundational across metabolic disease management in the same way we viewed statins as the de facto first line therapy in cardiology?

Again, I think there has been an evolution in how we use the incretin agents, and if you look at our guidelines, you know our diabetes guidelines used to say start with metformin, and then, if necessary, add another agent. Now our guidelines, of course, say that, in certain groups of patients with diabetes, so if patients have cardiovascular disease, have kidney disease, have heart failure, you start the GLP-1 RA as a first step. I think this is going to continue to broaden, and I think more and more patients will have GLP-1 RAs as very early therapy, as you know what one could call a potentially foundational agent.

Editors’ Note: This transcript has been edited for grammar and clarity using artificial intelligence tools.

Orland MD, et al. Can GLP-1 receptor agonists mitigate cancer progression? A propensity-matched analysis across seven solid tumors. Presented at: 2026 ASCO Annual Meeting; May 29–June 2, 2026; Chicago, IL. Abstract 3143.

Writing Committee Members; ACC/AHA Joint Committee on Clinical Practice Guidelines. 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome. J Am Coll Cardiol. 2026. doi:10.1016/j.jacc.2026.03.056.

GLP-1 receptor agonists have progressed from glucose-lowering drugs to pleiotropic metabolic therapies with evidence for weight loss and reductions in CV events, CKD, MASH, OSA, and osteoarthritis. Real-world ASCO 2026 analyses suggested 38%–50% lower odds of progression to stage IV disease versus DPP-4 inhibitors across obesity-associated lung, breast, colorectal, and liver cancers. Concurrently, CKM syndrome has been formalized by AHA and codified in 2026 ACC/AHA/ADA/ASN guidelines, favoring integrated care and positioning GLP-1 RAs as polypharmacy-sparing foundational agents. Anti-inflammatory mechanisms and broader oncologic signals remain under active study.

Leiter discusses the growth of incretin-based therapies through all aspects of the cardio-kidney-metabolic syndrome space.

Dyslipidemia

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

Frieden on expanding dupilumab use in pediatric skin conditions: prurigo nodularis, EB pruriginosa, and more.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Expanding Use of Dupilumab in Pediatric Patients, With Ilona Frieden, MD

Stay updated with the latest healthcare breakthroughs, including phase 3 data, new clinical findings, and regulatory updates.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

The HCPFive: Top News for Healthcare Providers from the Week of 06/21

At Maui Derm NP+PA Summer 2026, Matthew Zirwas, MD, shares cases of a factory worker with PPD allergy and a chronic spontaneous urticaria patient with persistent facial dermatitis.

When the Allergen Is Not What You Expected: 2 Contact Dermatitis Cases 

Jessica Glennie, MSN, APRN, says the first formal ATS clinical guidelines on interstitial lung abnormalities are filling a real gap — but integration into practice is still catching up.


Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Pulmonary Fibrosis

Interstitial Lung Abnormalities: Recognition, Risk Stratification, and When to Act

Leiter discusses the importance of earlier and more dramatic lipid-lowering interventions in patients with diabetes at risk of cardiovascular disease.

Q&A: Intensive LDL Lowering and Cardiovascular Prevention Strategies, With Lawrence Leiter, MD

Oksana Hamidi, DO, is an associate professor in the division of endocrinology and metabolism at UT Southwestern Medical Center

In the final episode, ‘Integrating Hypercortisolism Screening into Clinical Practice,’ the panelists explore practical strategies for improving recognition, screening, and management of hypercortisolism in routine clinical care. 

Video Series

Integrating Hypercortisolism Screening into Clinical Practice

This episode, titled ‘Management Strategies for Hypercortisolism,’ features panelists discussing the practical considerations involved in long-term management of hypercortisolism and the importance of maintaining sustained disease control while minimizing treatment-related complications. 

Management Strategies for Hypercortisolism

In ‘Monitoring and Maintaining Long-Term Disease Control in Hypercortisolism,’ our panel explores how clinicians balance sustained cortisol control with the need to manage long-term metabolic risk in patients with hypercortisolism. 

Monitoring and Maintaining Long-Term Disease Control in Hypercortisolism

In this episode, ‘Long-Term Treatment Adherence and Persistence in Hypercortisolism,’ the panelists explore the factors that influence long-term treatment success and the challenges of maintaining adherence to medical therapy in patients with hypercortisolism. 

Long-Term Treatment Adherence and Persistence in Hypercortisolism

This episode, titled ‘Evaluating Clinical and Real-World Evidence in Hypercortisolism,’ features panelists discussing key clinical trial findings, real-world treatment experiences, and emerging research that continue to shape the management of hypercortisolism. The expert faculty review efficacy, safety, and practical considerations associated with several established therapies while also exploring new insights into the relationship between cortisol excess and metabolic dysfunction.

Latest News

When to Add GLP-1 Receptor Agonists to Metreleptin in Lipodystrophy, With Lindsay Fourman, MD

Diabetes Dialogue: Tegoprubart and Freedom from Insulin in Type 1 Diabetes

New AI Tool May Effectively Predict Sudden Cardiac Arrest Risk in Otherwise Healthy Patients

FDA Approves Risankizumab for Pediatric Plaque Psoriasis, Psoriatic Arthritis

Q&A: GLP-1 Receptor Agonists and the Advent of CKM Syndrome, With Lawrence Leiter, MD